{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T23:25:15Z","timestamp":1716938715497},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,30]],"date-time":"2010-12-30T00:00:00Z","timestamp":1293667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00595-009-4226-z","type":"journal-article","created":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T16:01:03Z","timestamp":1293638463000},"page":"48-53","source":"Crossref","is-referenced-by-count":5,"title":["Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer"],"prefix":"10.1007","volume":"41","author":[{"given":"Kenichi","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadanori","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhisa","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadao","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motomi","family":"Shiono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,30]]},"reference":[{"key":"4226_CR1","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1200\/JCO.2005.06.002","volume":"23","author":"N.E. Davidson","year":"2005","unstructured":"Davidson NE, O\u2019Neill AM, Vukov AM, Osborne CK, Martino S, White DR, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005;23:5869\u20135872.","journal-title":"J Clin Oncol"},{"key":"4226_CR2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group.","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687\u20131717.","journal-title":"Lancet"},{"key":"4226_CR3","first-page":"84","volume":"9","author":"R.M. Chapman","year":"1982","unstructured":"Chapman RM. Effect of cytotoxic therapy on sexuality and gonadal function. Semin. Oncol 1982;9:84\u201394.","journal-title":"Oncol"},{"key":"4226_CR4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8","volume":"39","author":"H. Koyama","year":"1977","unstructured":"Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y, Terasawa T, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403\u20131409.","journal-title":"Cancer"},{"key":"4226_CR5","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J. Bines","year":"1996","unstructured":"Bines J, Oleske DM, Cobeleigh MA. Ovarian function in premenopausal woman treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718\u20131729.","journal-title":"J Clin Oncol"},{"key":"4226_CR6","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/jnci\/djg133","volume":"95","author":"J.L. Pater","year":"2003","unstructured":"Pater JL, Parulekar WR. Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer \u2014 another step forward. J Natl Cancer Inst 2003;95:1811\u20131812.","journal-title":"J Natl Cancer Inst"},{"key":"4226_CR7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02967466","volume":"7","author":"M. Matsumoto","year":"2000","unstructured":"Matsumoto M, Miyauchi M, Yamamoto N, Shishikura T, Imanaka N. Investigation of menstruation recovery after LH-RH agonist therapy for premenopausal patients with breast cancer. Breast Cancer 2000;7:237\u2013240.","journal-title":"Breast Cancer"},{"key":"4226_CR8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ijc.21358","volume":"118","author":"E. Tokunaga","year":"2006","unstructured":"Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mahino K, et al. Akt is frequently activated in HER2\/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 2006;118:284\u2013289.","journal-title":"Int J Cancer"},{"key":"4226_CR9","unstructured":"Dako HercepTest\u2122 for immunoenzymatic staining (package insert). DAKO A\/S, Glastrup, Denmark; 1999."},{"key":"4226_CR10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2559.2008.03191.x","volume":"54","author":"D. Faratian","year":"2009","unstructured":"Faratian D, Munro A, Twelves C, Bartlett JM. Membranous and cytoplasmic staining of Ki-67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology 2009;54:254\u2013257.","journal-title":"Histopathology"},{"key":"4226_CR11","first-page":"104","volume":"ii","author":"G.W. Beatson","year":"1895","unstructured":"Beatson GW. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 1895;ii:104\u2013107, 162\u20135.","journal-title":"Lancet"},{"key":"4226_CR12","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jnci\/djg119","volume":"95","author":"International Breast Cancer Study Group","year":"2003","unstructured":"International Breast Cancer Study Group (IBCSG). Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer. a randomized trial. J Natl Cancer Inst 2003;95:1833\u20131846.","journal-title":"J Natl Cancer Inst"},{"key":"4226_CR13","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.1999.17.8.2365","volume":"17","author":"P.J. Goodwin","year":"1999","unstructured":"Goodwin PJ, Ennis M, Protchard KI, McCready D, Koo J, Sidlofsky S, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365\u20132370.","journal-title":"J Clin Oncol"},{"key":"4226_CR14","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1200\/JCO.2006.07.2793","volume":"24","author":"J.M. Walshe","year":"2006","unstructured":"Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24:5769\u20135779.","journal-title":"J Clin Oncol"},{"key":"4226_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0885-3924(02)00379-2","volume":"23","author":"M.A. Weitzer","year":"2002","unstructured":"Weitzer MA, Moncello J, Jacobsen PB, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002;23:337\u2013345.","journal-title":"J Pain Symptom Manage"},{"key":"4226_CR16","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1210\/jc.81.12.4453","volume":"81","author":"T. Saarto","year":"1996","unstructured":"Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J Clin Endocrinol Metab 1996;81:4453\u20134457.","journal-title":"J Clin Endocrinol Metab"},{"key":"4226_CR17","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/S0959-8049(01)00317-3","volume":"37","author":"L. Vehmanen","year":"2001","unstructured":"Vehmanen L, Saarto T, Elomaa I, M\u00e4kel\u00e4 P, V\u00e4lim\u00e4ki M, Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001;37:2373\u20132378.","journal-title":"Eur J Cancer"},{"key":"4226_CR18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/gyno.2001.6181","volume":"81","author":"B.P. Pacheco","year":"2001","unstructured":"Pacheco BP, Ribas LMM, Milone G, Fernandez I, Kvicala R, Mila T, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81:391\u2013397.","journal-title":"Gynecol Oncol"},{"key":"4226_CR19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood.V58.4.849.849","volume":"58","author":"R.M. Chapman","year":"1981","unstructured":"Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in woman receiving chemotherapy for Hodgkin\u2019s disease. Blood 1981;58:849\u2013851.","journal-title":"Blood"},{"key":"4226_CR20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0959-8049(93)90569-2","volume":"29","author":"L.M. Reyno","year":"1992","unstructured":"Reyno LM, Levine MN, Skingley P, Arnold A, Abu Zahra H. Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer 1992;29:21\u201323.","journal-title":"Eur J Cancer"},{"key":"4226_CR21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/1097-0142(19900215)65:4<847::AID-CNCR2820650402>3.0.CO;2-A","volume":"65","author":"R. Sutton","year":"1990","unstructured":"Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 1990;65:847\u2013850.","journal-title":"Cancer"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-009-4226-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00595-009-4226-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-009-4226-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T02:20:27Z","timestamp":1592187627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00595-009-4226-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,30]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["4226"],"URL":"https:\/\/doi.org\/10.1007\/s00595-009-4226-z","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,30]]}}}